Valeo Pharma Inc.
VPHIF · OTC
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | -0.03 | -0.87 |
| FCF Yield | -169.54% | -65.77% | -26.81% | -12.63% |
| EV / EBITDA | -6.16 | -5.76 | -5.88 | -14.31 |
| Quality | ||||
| ROIC | -67.29% | -42.88% | -120.97% | -64.37% |
| Gross Margin | 24.26% | 22.64% | 29.17% | 18.49% |
| Cash Conversion Ratio | 0.56 | 1.11 | 0.87 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 58.43% | 54.87% | 27.27% | 19.46% |
| Free Cash Flow Growth | 39.97% | -124.30% | -135.42% | -106.12% |
| Safety | ||||
| Net Debt / EBITDA | -5.06 | -2.42 | -0.51 | -0.11 |
| Interest Coverage | -1.25 | -3.03 | -9.45 | -7.26 |
| Efficiency | ||||
| Inventory Turnover | 3.99 | 2.15 | 1.25 | 6.91 |
| Cash Conversion Cycle | 100.35 | 177.57 | 53.18 | -100.38 |